Drug-Induced Immune Hemolytic Anemia Market
Market Insights on Drug-Induced Immune Hemolytic Anemia covering sales outlook, demand forecast & up-to-date key trends
Drug-Induced Immune Hemolytic Anemia Market :Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031
Drug-Induced Immune Hemolytic Anemia Market Overview
According to the latest research by FMI, Drug-Induced Immune Hemolytic Anemia is set to witness a growth CAGR of 8.4% during the year 2021-2031. The drug-induced immune hemolytic anemia is a rare cause of anemia often associated with poor outcomes including organ failure and even death.
The development of drug-induced immune hemolytic anemia is principally due to antibody development. The drug-induced immune hemolytic anemia market is expected to grow at a moderate pace due to the development and discovery of new drugs and the rising application of pharmacovigilance for drug imputability. The most common agents for drug-induced immune hemolytic anemia are cephalosporin and penicillin.
What is Driving Demand for Drug-Induced Immune Hemolytic Anemia?
The number of drugs and their suggested mechanisms associated with drug-induced immune hemolytic anemia have witnessed a significant change over the past 4 decades in terms of number of implicated drugs. According to the American Society of Hematology, a reported number of 125 drugs are associated with drug-induced immune hemolytic anemia as per 2017 data of reviewed publications.
The three groups of drugs identified as predominant were antimicrobials which accounted for 42% of the implicated drugs, anti-inflammatory (15%) and anti-neoplastics (11%). The advancements in clinical pharmacology and the increasing number of reviewed case-based studies on the cause and mechanisms of drug-induced immune hemolytic anemia have resulted as drivers in case identification and timely drug withdrawal and hence are set to increase the business growth.
Which factors are likely to augment growth of Drug-Induced Immune Hemolytic Anemia?
The clinical expression of drug-induced immune hemolytic anemia is generally mild, but it is also witnessed to develop into acute severe hemolytic anemia and even death. The increasing number in the reports of second and third generation cephalosporin which lead to clinical hemolysis are set to act as augmentative factors for the drug-induced immune hemolytic anemia.
U.S. and Canada Drug-Induced Immune Hemolytic Anemia Outlook
The principal cases of drug-induced immune hemolytic anemia are identified after post-operative conditions. The region of North America holds a significant share in the identification and measures for mitigation and improvement of patient health during this period and will continue to do so over the forecast period.
This is facilitated by the presence of advanced healthcare infrastructure, robust pharmacovigilance programs and high participation of providers in clinical programs on drug-induced immune hemolytic anemia. The American Association of Blood Banks is an active moderator of drug-induced immune hemolytic anemia market.
Europe Demand Outlook for Drug-Induced Immune Hemolytic Anemia
The outlook for drug-induced immune hemolytic anemia in the European region is expected to show a moderate influence over the forecast period. This is associated with the development of appropriate clinical guidelines by British Society for Hematology and management of drug-induced immune hemolytic anemia in post-operative situations.
Who are the Key Manufacturers and Suppliers of Drug-Induced Immune Hemolytic Anemia?
The key companies operating in Drug-Induced Immune Hemolytic Anemia are
- ARUP Laboratories
- Creative Biolabs
- machaon diagnostics
- F. Hoffmann-La Roche Ltd.
- Baxter International Inc.
- Pfizer Inc
- Zydus Cadila
- Amneal Pharmaceuticals Inc
- Incyte Corp
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
By Drug Type:
- Penicillin and its derivatives
- Phenazopyridine (pyridium)
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
By End User:
- Clinical Laboratories
- North America
- Latin America
- South Asia
- Rest of South Asia
- East Asia
- South Korea
- Middle East and Africa
- GCC Countries
- South Africa